Drug repurposing screen identifies Foxo1-dependent angiopoietin-2 regulation in sepsis

Critical Care Medicine

Volumn 43, Issue 7, 2015, Pages e230-e240

  Ghosh, Chandra C ^a   Thamm, Kristina ^b   Berghelli, Anthony V ^a   Schrimpf, Claudia ^b   Maski, Manish R ^a   Abid, Tanaz ^a   Milam, Katelyn E ^a   Rajakumar, Augustine ^a   Santel, Ansgar ^c   Kielstein, Jan T ^b   Ahmed, Asif ^d   Thickett, David ^e   Wang, Keqin ^e   Chase, Maureen ^a   Donnino, Michael W ^a   Aird, William C ^a   Haller, Hermann ^b   David, Sascha ^a,b   Parikh, Samir M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Silence Therapeutics GmbH   (Germany)

^d ASTON UNIVERSITY   (United Kingdom)

^e UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

angiopoietin 2; endothelium; Foxo1; sepsis; statin; Tie2

Indexed keywords

ANGIOPOIETIN 2; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; SIMVASTATIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FKHR; ANGIOPOIETIN-2; FORKHEAD TRANSCRIPTION FACTORS; FOXO1 PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

ARTICLE; CELL CULTURE; COHORT ANALYSIS; CRITICALLY ILL PATIENT; DRUG MECHANISM; DRUG REPOSITIONING; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; PROTEIN PHOSPHORYLATION; RETROSPECTIVE STUDY; SEPSIS; SIGNAL TRANSDUCTION; SURVIVAL RATE; VASCULAR ENDOTHELIUM; AGED; ANIMALS; ANTAGONISTS AND INHIBITORS; CASE-CONTROL STUDIES; CONTROLLED STUDY; FEMALE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

AGED; ANGIOPOIETIN-2; ANIMALS; CASE-CONTROL STUDIES; DRUG REPOSITIONING; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; SEPSIS; SIMVASTATIN;

EID: 84937575236     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000000993     Document Type: Article

References (46)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348(16):1546-1554.
2. Ranieri VM, Thompson BT, Barie PS, et al. PROWESS-SHOCK Study Group: Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366:2055-2064
3. Parikh SM, Mammoto T, Schultz A, et al. Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med 2006; 3:e46
4. Calfee CS, Gallagher D, Abbott J, et al. NHLBI ARDS Network: Plasma angiopoietin-2 in clinical acute lung injury: Prognostic and pathogenetic significance. Crit Care Med 2012; 40:1731-1737
5. Giuliano JS Jr, Lahni PM, Harmon K, et al. Admission angiopoietin levels in children with septic shock. Shock 2007; 28:650-654
6. Kumpers P, Lukasz A, David S, et al. Excess circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical patients. Crit Care 2008; 12:R147
7. Ricciuto DR, dos Santos CC, Hawkes M, et al. Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis. Crit Care Med 2011; 39:702-710
8. David S, Mukherjee A, Ghosh CC, et al. Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis. Crit Care Med 2012; 40:3034-3041
9. Fiedler U, Scharpfenecker M, Koidl S, et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004; 103:4150-4156
10. Wong AL, Haroon ZA, Werner S, et al. Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res 1997; 81:567-574
11. Yuan HT, Khankin EV, Karumanchi SA, et al. Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol 2009; 29:2011-2022
12. Fiedler U, Reiss Y, Scharpfenecker M, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-Alpha and has a crucial role in the induction of inflammation. Nat Med 2006; 12:235-239
13. Scharpfenecker M, Fiedler U, Reiss Y, et al. The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci 2005; 118:771-780
14. David S, Ghosh CC, Kumpers P, et al. Effects of a synthetic PEGylated Tie-2 agonist peptide on endotoxemic lung injury and mortality. Am J Physiol Lung Cell Mol Physiol 2011; 300:L851-L862
15. David S, Park JK, Meurs Mv, et al. Acute administration of recombinant Angiopoietin-1 ameliorates multiple-organ dysfunction syndrome and improves survival in murine sepsis. Cytokine 2011; 55:251-259
16. Witzenbichler B, Westermann D, Knueppel S, et al. Protective role of angiopoietin-1 in endotoxic shock. Circulation 2005; 111:97-105
17. Ziegler T, Horstkotte J, Schwab C, Pfetsch V, Weinmann K, Dietzel S, Rohwedder I, Hinkel R, Gross L, Lee S et al. Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis. J Clin Invest 2013; 123:3436-3445
18. Tabruyn SP, Colton K, Morisada T, et al. Angiopoietin-2-driven vascular remodeling in airway inflammation. Am J Pathol 2010; 177:3233-3243
19. van Nieuw Amerongen GP, Vermeer MA, Negre-Aminou P, et al. Simvastatin improves disturbed endothelial barrier function. Circulation 2000; 102:2803-2809
20. Ando H, Takamura T, Ota T, et al. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther 2000; 294:1043-1046
21. Merx MW, Liehn EA, Janssens U, et al. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 2004; 109:2560-2565
22. Merx MW, Liehn EA, Graf J, et al. Statin treatment after onset of sepsis in a murine model improves survival. Circulation 2005; 112:117-124
23. Kruger PS, Harward ML, Jones MA, et al. Continuation of statin therapy in patients with presumed infection: A randomized controlled trial. Am J Respir Crit Care Med 2011; 183:774-781
24. Papazian L, Roch A, Charles PE, et al. STATIN-VAP Study Group: Effect of statin therapy on mortality in patients with ventilator-Associated pneumonia: A randomized clinical trial. JAMA 2013; 310:1692-1700
25. Patel JM, Snaith C, Thickett DR, et al. Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial). Crit Care 2012; 16:R231
26. Truwit JD, Bernard GR, Steingrub J, Matthay MA, Liu KD, Albertson TE, Brower RG, Shanholtz C, Rock P, Douglas IS et al. Rosuvastatin for sepsis-Associated acute respiratory distress syndrome. N Engl J Med 2014, 370:2191-2200.
27. McAuley DF, Laffey JG, O'Kane CM, et al. HARP-2 Investigators; Irish Critical Care Trials Group: Simvastatin in the acute respiratory distress syndrome. N Engl J Med 2014; 371:1695-1703
28. Rittirsch D, Huber-Lang MS, Flierl MA, et al. Immunodesign of experimental sepsis by cecal ligation and puncture. Nat Protoc 2009; 4:31-36
29. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277:55-60
30. Hilbert T, Poth J, Frede S, et al. Anti-Atherogenic effects of statins: Impact on angiopoietin-2 release from endothelial cells. Biochem Pharmacol 2013; 86:1452-1460
31. Daly C, Wong V, Burova E, et al. Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1). Genes Dev 2004; 18:1060-1071
32. Kawanami D, Mahabeleshwar GH, Lin Z, et al. Kruppel-like factor 2 inhibits hypoxia-inducible factor 1alpha expression and function in the endothelium. J Biol Chem 2009; 284:20522-20530
33. Parmar KM, Nambudiri V, Dai G, et al. Statins exert endothelial atheroprotective effects via the KLF2 transcription factor. J Biol Chem 2005; 280:26714-26719
34. Sen-Banerjee S, Mir S, Lin Z, et al. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation 2005; 112:720-726
35. Hegen A, Koidl S, Weindel K, et al. Expression of angiopoietin-2 in endothelial cells is controlled by positive and negative regulatory promoter elements. Arterioscler Thromb Vasc Biol 2004; 24:1803-1809
36. Santel A, Aleku M, Keil O, et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 2006; 13:1222-1234
37. Terblanche M, Almog Y, Rosenson RS, et al. Statins and sepsis: Multiple modifications at multiple levels. Lancet Infect Dis 2007; 7:358-368
38. Bhandari V, Choo-Wing R, Lee CG, et al. Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. Nat Med 2006; 12:1286-1293
39. Parikh SM. Dysregulation of the angiopoietin-Tie-2 axis in sepsis and ARDS. Virulence 2013; 4:517-524
40. Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6:1004-1010
41. Pleiner J, Schaller G, Mittermayer F, et al. Simvastatin prevents vascular hyporeactivity during inflammation. Circulation 2004; 110:3349-3354
42. Jacobson JR, Dudek SM, Birukov KG, et al. Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am J Respir Cell Mol Biol 2004; 30:662-670
43. David S, Ghosh CC, Mukherjee A, Parikh SM. Angiopoietin-1 requires IQ domain GTPase-Activating protein 1 to activate Rac1 and promote endothelial barrier defense. Arterioscler Thromb Vasc Biol 2011; 31:2643-2652.
44. Mammoto T, Parikh SM, Mammoto A, et al. Angiopoietin-1 requires p190 RhoGAP to protect against vascular leakage in vivo. J Biol Chem 2007; 282:23910-23918
45. Dharaneeswaran H, Abid MR, Yuan L, et al. FOXO1-mediated activation of Akt plays a critical role in vascular homeostasis. Circ Res 2014; 115:238-251
46. Kruger PS, Venkatesh B. Are there any benefits from statin treatment for the septic patient? Curr Atheroscler Rep 2014; 16:378